Key Takeaways
- • NAVER D2SF, the corporate venture capital arm of South Korean internet giant NAVER, invested in ImpriMed's $10 million Series A2 bridge financing round, led by LB Investment with Samsung Securities and other new investors participating.
- • ImpriMed's xCellSense platform combines ex vivo analysis of live patient-derived cancer cells with multimodal AI to support personalized cancer treatment decisions, with blood cancers as the primary commercialization target for human medicine.
- • The startup has already completed over 27,000 tests in veterinary oncology, serving more than 600 veterinary hospitals, and has received innovative medical device designation in South Korea.
- • ImpriMed is targeting U.S. FDA clearance and CLIA certification by Q1 2027, marking a critical inflection point for commercialization in the human oncology market.
- • The investment reflects growing strategic interest among South Korean technology companies in AI-driven precision medicine platforms with viable near-term regulatory pathways.
Summary
NAVER D2SF, the corporate venture capital arm of South Korea's internet giant NAVER, has invested in ImpriMed, a Silicon Valley-based AI precision medicine startup, as part of the company's $10 million Series A2 bridge financing round. The round was led by LB Investment, with Samsung Securities and other new institutional investors joining the participation. This move underscores NAVER D2SF's expanding presence in North American healthcare technology and reflects broader strategic interest among South Korean conglomerates in commercializable AI-driven medical technologies.
ImpriMed, founded in 2017 in Silicon Valley, has developed the xCellSense platform, a treatment decision support system that integrates ex vivo analysis of live patient-derived cancer cells with genomic, immunophenotypic, and clinical data through multimodal AI models. The platform maintains patient cancer cells in a viable state outside the body for extended periods, enabling assessment of cellular biological characteristics and drug sensitivity. This data is then synthesized with multi-dimensional clinical information to provide precision treatment recommendations, with blood cancers serving as the primary focus for human oncology commercialization.
The company has already achieved significant traction in veterinary oncology, having completed over 27,000 tests and established partnerships with more than 600 veterinary hospitals. Additionally, ImpriMed has received innovative medical device designation in South Korea, establishing regulatory credibility in a key Asian market. The company is now on an accelerated path toward human medicine commercialization, targeting U.S. FDA clearance and Clinical Laboratory Improvement Amendments (CLIA) certification by the first quarter of 2027—a regulatory timeline that positions ImpriMed as a near-term commercialization candidate in precision oncology.
The investment by NAVER D2SF represents a calculated entry into an emerging sector where AI-enabled live-cell diagnostics have the potential to significantly improve treatment outcomes and reduce trial-and-error drug selection in cancer care. The participation of established institutional investors such as Samsung Securities alongside the lead investor LB Investment suggests confidence in both the technology platform and the regulatory pathway toward human clinical adoption.
ImpriMed, founded in 2017 in Silicon Valley, has developed the xCellSense platform, a treatment decision support system that integrates ex vivo analysis of live patient-derived cancer cells with genomic, immunophenotypic, and clinical data through multimodal AI models. The platform maintains patient cancer cells in a viable state outside the body for extended periods, enabling assessment of cellular biological characteristics and drug sensitivity. This data is then synthesized with multi-dimensional clinical information to provide precision treatment recommendations, with blood cancers serving as the primary focus for human oncology commercialization.
The company has already achieved significant traction in veterinary oncology, having completed over 27,000 tests and established partnerships with more than 600 veterinary hospitals. Additionally, ImpriMed has received innovative medical device designation in South Korea, establishing regulatory credibility in a key Asian market. The company is now on an accelerated path toward human medicine commercialization, targeting U.S. FDA clearance and Clinical Laboratory Improvement Amendments (CLIA) certification by the first quarter of 2027—a regulatory timeline that positions ImpriMed as a near-term commercialization candidate in precision oncology.
The investment by NAVER D2SF represents a calculated entry into an emerging sector where AI-enabled live-cell diagnostics have the potential to significantly improve treatment outcomes and reduce trial-and-error drug selection in cancer care. The participation of established institutional investors such as Samsung Securities alongside the lead investor LB Investment suggests confidence in both the technology platform and the regulatory pathway toward human clinical adoption.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.